SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thurein Htoo, MS, MBA, CEO of Qlaris Bio, discusses how the company is targeting episcleral venous pressure in the treatment of glaucoma. QLS-101, Qlaris Bio’s novel topical drug therapy, acts to reduce episcleral venous pressure, therefore reducing IOP.
Glaucoma 360 attendees voted Htoo’s presentation the winner of the Best Pitch Award.
Uncategorized